DK2937358T3 - Fremgangsmåder til behandling af multipel sklerose under anvendelse af antisense-oligonukleotider - Google Patents

Fremgangsmåder til behandling af multipel sklerose under anvendelse af antisense-oligonukleotider Download PDF

Info

Publication number
DK2937358T3
DK2937358T3 DK15155831.9T DK15155831T DK2937358T3 DK 2937358 T3 DK2937358 T3 DK 2937358T3 DK 15155831 T DK15155831 T DK 15155831T DK 2937358 T3 DK2937358 T3 DK 2937358T3
Authority
DK
Denmark
Prior art keywords
methods
multiple sclerosis
antisense oligonucleotides
treating multiple
treating
Prior art date
Application number
DK15155831.9T
Other languages
Danish (da)
English (en)
Inventor
Ety Klinger
Shoshi Tessler
Hussein Hallak
George Tachas
Mark Paul Diamond
Original Assignee
Antisense Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisense Therapeutics Ltd filed Critical Antisense Therapeutics Ltd
Application granted granted Critical
Publication of DK2937358T3 publication Critical patent/DK2937358T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK15155831.9T 2008-06-23 2009-06-23 Fremgangsmåder til behandling af multipel sklerose under anvendelse af antisense-oligonukleotider DK2937358T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13297308P 2008-06-23 2008-06-23
EP09798248.2A EP2318424B1 (en) 2008-06-23 2009-06-23 Methods for treating multiple sclerosis using antisense oligonucleotides

Publications (1)

Publication Number Publication Date
DK2937358T3 true DK2937358T3 (da) 2019-01-02

Family

ID=41550900

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15155831.9T DK2937358T3 (da) 2008-06-23 2009-06-23 Fremgangsmåder til behandling af multipel sklerose under anvendelse af antisense-oligonukleotider
DK09798248T DK2318424T3 (en) 2008-06-23 2009-06-23 A method for the treatment of multiple sclerosis by the use of antisense oligonucleotides

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09798248T DK2318424T3 (en) 2008-06-23 2009-06-23 A method for the treatment of multiple sclerosis by the use of antisense oligonucleotides

Country Status (8)

Country Link
US (2) US8415314B2 (enExample)
EP (2) EP2318424B1 (enExample)
JP (2) JP5988581B2 (enExample)
AU (1) AU2009271678B2 (enExample)
CA (1) CA2728562C (enExample)
DK (2) DK2937358T3 (enExample)
ES (2) ES2699891T3 (enExample)
WO (1) WO2010008474A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728562C (en) 2008-06-23 2018-10-23 Ety Klinger Methods for treating multiple sclerosis using antisense oligonucleotides
CA2811228C (en) * 2010-09-17 2023-03-14 Antisense Therapeutics Ltd Method for reducing circulating leukocytes in a human subject
US10376536B2 (en) 2015-05-11 2019-08-13 Murdoch University Multiple sclerosis treatment
US11891606B2 (en) * 2017-06-16 2024-02-06 Antisense Therapeutics Ltd Methods for treating multiple sclerosis using antisense oligonucleotides
JP7604361B2 (ja) * 2018-05-04 2024-12-23 アンチセンス セラピューティクス リミテッド 治療での使用及び方法
KR20220061915A (ko) * 2019-05-06 2022-05-13 안티센스 테라퓨틱스 엘티디 Cd49d에 대한 억제성 올리고뉴클레오티드를 사용하는 근이영양증의 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242591B1 (en) * 1997-10-15 2001-06-05 Isis Pharmaceuticals, Inc. Synthesis of sulfurized 2'-substituted oligonucleotides
US5968826A (en) * 1998-10-05 1999-10-19 Isis Pharmaceuticals Inc. Antisense inhibition of integrin α4 expression
US20070237717A1 (en) * 2004-04-05 2007-10-11 Roland Martin Methods for Selection of Subjects for Multiple Sclerosis Therapy
JP2008516991A (ja) * 2004-10-20 2008-05-22 アンチセンス セラピューティクス リミテッド インテグリンα４発現のアンチセンス調節
CA2728562C (en) 2008-06-23 2018-10-23 Ety Klinger Methods for treating multiple sclerosis using antisense oligonucleotides

Also Published As

Publication number Publication date
EP2937358A1 (en) 2015-10-28
JP6131230B2 (ja) 2017-05-17
JP5988581B2 (ja) 2016-09-07
ES2699891T3 (es) 2019-02-13
DK2318424T3 (en) 2015-04-07
EP2318424A2 (en) 2011-05-11
EP2318424A4 (en) 2012-12-26
WO2010008474A3 (en) 2010-04-22
JP2015044824A (ja) 2015-03-12
CA2728562A1 (en) 2010-01-21
AU2009271678B2 (en) 2013-09-19
WO2010008474A4 (en) 2011-01-27
ES2532404T3 (es) 2015-03-26
US20100119480A1 (en) 2010-05-13
US20130345293A1 (en) 2013-12-26
AU2009271678A1 (en) 2010-01-21
CA2728562C (en) 2018-10-23
WO2010008474A2 (en) 2010-01-21
EP2937358B1 (en) 2018-09-19
US8759314B2 (en) 2014-06-24
JP2011525531A (ja) 2011-09-22
US8415314B2 (en) 2013-04-09
EP2318424B1 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
IL232222A0 (en) Methods for treating progressive multiple sclerosis
EP2262892A4 (en) EXPRESSION OF HETEROLOGOUS SEQUENCES
DK2417257T3 (da) Tricyclo-dna-antisense-oligonukleotider, sammensætninger, og fremgangsmåder til behandlingen af sygdom
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
EP2310144A4 (en) COATINGS
BRPI0910854A2 (pt) métodos de tratamento
DK2448637T3 (da) Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi
BRPI0910259A2 (pt) métodos de tratamento de inflamação
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
BRPI0917575A2 (pt) métodos de tratamento de talassemia
DK3121280T3 (da) Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
BRPI0921482A2 (pt) tratamento de leucemia linfoblástica aguda
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
DK2350116T3 (da) Behandling af biofilm
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0919127A2 (pt) métodos para tratamento de água
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
IT1392670B1 (it) Iniettore
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
DK2164572T3 (da) Carbamoyl-cyclohexaner til behandling af akut mani
BRPI0920224A2 (pt) inibição de plgf para tratar leucemia positiva para cromossoma filadélfia
DK2131841T3 (da) Fremgangsmåder til behandling af akut smerte
DE112009002122A5 (de) Beschichtungsverfahren
BRPI0822129A2 (pt) Inibidores de aldh-2c no tratamento de vício.